Biofrontera Inc. (BFRI): Price and Financial Metrics


Biofrontera Inc. (BFRI): $2.61

-0.07 (-2.61%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

BFRI Stock Price Chart Interactive Chart >

Price chart for BFRI

BFRI Price/Volume Stats

Current price $2.61 52-week high $14.63
Prev. close $2.68 52-week low $2.20
Day low $2.44 Volume 235,200
Day high $2.68 Avg. volume 2,512,426
50-day MA $3.37 Dividend yield N/A
200-day MA $0.00 Market Cap 44.64M

Biofrontera Inc. (BFRI) Company Bio


Biofrontera Inc., a biopharmaceutical company, develops and provides dermatological products for the treatment of skin diseases in the United States. It primarily develops therapies for non-melanoma skin cancer. It offers Ameluz, an aminolevulinic acid hydrochloride gel for the photodynamic therapy of actinic keratoses; and BF-RhodoLED, an LED lamp emitting red light for use in photodynamic therapy. The company was founded in 1997 and is based in Woburn, Massachusetts.


BFRI Latest News Stream


Event/Time News Detail
Loading, please wait...

BFRI Latest Social Stream


Loading social stream, please wait...

View Full BFRI Social Stream

Latest BFRI News From Around the Web

Below are the latest news stories about Biofrontera Inc that investors may wish to consider to help them evaluate BFRI as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Good morning, trader!

William White on InvestorPlace | February 23, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Rise and shine, trader!

William White on InvestorPlace | February 17, 2022

Biofrontera Inc. provides Update on Patient Recruitment for Phase III Study for the Treatment of sBCC with Ameluz®-PDT

WOBURN, Mass., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, is pleased to provide an update on the patient recruitment for the phase III clinical study for the treatment of superficial basal cell carcinoma (sBCC) with Ameluz® photodynamic therapy (Ameluz®-PDT) in combination with the BF-RhodoLED® lamp in the U.S. To date, 70% of the planned 186 patients have been en

Yahoo | February 1, 2022

Biofrontera Inc. Issues Letter to Shareholders Highlighting 2021 Successes and Key Elements of the Strategic Plan for 2022 and Beyond

WOBURN, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, today issued the following letter from CEO Erica Monaco and Executive Chairman of the Board Hermann Lübbert. To our valued stockholders, We would like to extend warm wishes to all of you for a healthy and prosperous 2022. At Biofrontera Inc., we welcomed the New Year with optimism and continued business mom

Yahoo | January 18, 2022

Biofrontera Inc. Announces Preliminary Revenue for the Fourth Quarter and Full Year 2021

WOBURN, Mass., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced preliminary, unaudited revenue for the quarter and full year ended December 31, 2021. Revenue for the fourth quarter of 2021 is anticipated to be in the range of approximately $9.1 million to $9.2 million, an increase of approximately 7% over the same quarter last year. Revenue for the full

Yahoo | January 13, 2022

Read More 'BFRI' Stories Here

BFRI Price Returns

1-mo -30.77%
3-mo -14.43%
6-mo -2.25%
1-year N/A
3-year N/A
5-year N/A
YTD -65.29%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7707 seconds.